US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Nuvation Bio Inc.

News headline image
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Present at The Citizens Life Sciences Conference
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Present at the Jefferies London Healthcare Conference
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB
News headline image
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
From Nuvation Bio Inc.
Via Business Wire
Tickers NUVB